Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
Your view on CORT
Overview
What the company does, where it operates, and who runs it.
About Corcept Therapeutics Incorporated
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Joseph K. Belanoff
- Headquarters
- 149 Commonwealth Drive, Menlo Park, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Joseph K. Belanoff
- Headquarters
- 149 Commonwealth Drive, Menlo Park, CA, US
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States.
The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess.
The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays.
Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Corcept Therapeutics Incorporated, and the rating behind it. CORT last traded at $112.79, 216.5× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Corcept Therapeutics Incorporated. Starting points for Corcept Therapeutics Incorporated: P/E 216.5, EPS $0.52, beta 0.45 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Corcept Therapeutics Incorporated. Corcept Therapeutics Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Corcept Therapeutics Incorporated. Trailing twelve-month EPS for Corcept Therapeutics Incorporated stands at $0.52. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Corcept Therapeutics Incorporated. Corcept Therapeutics Incorporated has reported as a listed company since 2004. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Corcept Therapeutics Incorporated valued side by side against its closest peers. Corcept Therapeutics Incorporated is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Corcept Therapeutics Incorporated, and how their positions are changing. At a $12.19B market value, institutional positions materially move Corcept Therapeutics Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Corcept Therapeutics Incorporated executives and directors. Shares of Corcept Therapeutics Incorporated have traded between $49.00 and $117.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Corcept Therapeutics Incorporated. Corcept Therapeutics Incorporated is a $12.19B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Corcept Therapeutics Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Corcept Therapeutics Incorporated. Coverage tracks Corcept Therapeutics Incorporated within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.